{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:53:05Z","timestamp":1781153585875,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the frequency of hypophysitis and hypopituitarism in cancer patients who are undergoing antineoplastic treatment with immunotherapy, as well as to describe the clinical, epidemiological, and demographic characteristics of these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of the literature in PubMed, Embase, Web of Science, ClinicalTrials.gov and Cochrane Controlled Register of Trials took place on May 8 and 9, 2020. Randomized and nonrandomized clinical trials, cohort studies, case-control studies, case series and case reports were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 239 articles were obtained, in which 963 cases of hypophysitis and 128 cases of hypopituitarism were found in a treated population of 30,014 individuals (3.20% and 0.42% of the evaluated population, respectively). In the cohort studies, the incidence of hypophysitis and hypopituitarism ranged from 0% to 27.59% and from 0% to 17.86%, respectively. In the non-randomized clinical trials, the incidence of hypophysitis and hypopituitarism ranged from 0% to 25% and from 0% to 14.67%, and in randomized clinical trials from 0% to 16.2% and from 0% to 33.33%. The most common hormonal changes were in the corticotrophic, thyrotrophic and gonadotrophic axes. The main magnetic resonance imaging (MRI) findings were enlargement of the pituitary gland and enhanced contrast uptake. The main symptoms presented by patients with hypophysitis were fatigue and headache.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present review reported a frequency of hypophysitis and hypopituitarism of 3.20% and 0.42%, respectively, in the evaluated population. The clinical-epidemiological characteristics of patients affected by hypophysitis were also described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42020175864.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1091185","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T05:47:31Z","timestamp":1676440051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Frequency and clinical characteristics of hypophysitis and hypopituitarism in patients undergoing immunotherapy \u2013 A systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Juliana Prud\u00eancio","family":"Jacques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Pinto","family":"Valadares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Castelo","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Regina Fernandes","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Ansaneli","family":"Naves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"B1","unstructured":"Cancer - fact-sheets"},{"key":"B2","first-page":"1","article-title":"Diretrizes brasileiras de manejo de toxicidades imunomediadas associadas ao uso de bloqueadores de correceptores imunes","volume":"13","author":"Wainstein","year":"2017","journal-title":"Braz J Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: Review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B5","unstructured":"PROSPERO"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-20-01","author":"Aromataris","year":"2020","journal-title":"JBI Manual for Evidence Synthesis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.107","article-title":"Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy","volume":"114","author":"Bowyer","year":"2016","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2019.1887","article-title":"Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis","volume":"11","author":"Numakura","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.04.004","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma and end-stage renal disease at 2 centers","volume":"17","author":"Tachibana","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31828eed39","article-title":"Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma","volume":"36","author":"Wilgenhof","year":"2013","journal-title":"J Immunother."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial","volume":"13","author":"Van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0025","article-title":"Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced\/metastatic gastric or gastroesophageal junction cancer","volume":"23","author":"Bang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B17","unstructured":"A randomized, open-label, phase 2 safety and efficacy trial of ipilimumab versus pemetrexed in subjects with Recurrent\/Stage IV non-squamous, non-small cell lung cancer who have not progressed after four cycles of a platinum-based first line c"},{"key":"B18","unstructured":"A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of avelumab (msb0010718c) in combination with and\/or following chemotherapy in patients with previously untreated epithelial ovarian cancer javelin ovaria"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: Review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0984-z","article-title":"Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)","volume":"42","author":"Ruggeri","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2014.10.011","article-title":"Hypophysitis","volume":"44","author":"Fukuoka","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2661","article-title":"Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis","volume":"8","author":"Lu","year":"2019","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S196316","article-title":"Immune-related adverse events following administration of anti-cytotoxic t-lymphocyte-associated protein-4 drugs: A comprehensive systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/imt-2016-0147","article-title":"Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: A systematic review and meta-analysis","volume":"9","author":"Shang","year":"2017","journal-title":"Immunotherapy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000593","article-title":"Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma","volume":"29","author":"Mangana","year":"2019","journal-title":"Melanoma Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2258","article-title":"E3611\u2013a randomized phase II study of ipilimumab at 3 or 10 mg\/kg alone or in combination with high-dose interferon-a2b in advanced melanoma","volume":"25","author":"Tarhini","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber cancer institute, Massachusetts general hospital, memorial Sloan-Kettering cancer center, and university hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1974297","article-title":"Recent insights into the pathogenesis of autoimmune hypophysitis","volume":"17","author":"Frasca","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1091185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T05:47:38Z","timestamp":1676440058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1091185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":36,"alternative-id":["10.3389\/fendo.2023.1091185"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1091185","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"1091185"}}